If approved, cagrilintide/semaglutide would be the first amylin/GLP-1 combination for weight management
Wegovy is indicated for people ages 12 years and older who have: A BMI of 30 kg/m 2 or higher A BMI of 27 kg/m 2 to 29.9 kg/m 2 and at least one weight-related comorbidity , such as high blood pressure, type 2 diabetes, or obstructive sleep apnea Wegovy is also indicated to reduce the risk of major cardiovascular events , such as heart attack or stroke, in people who have obesity or overweight
Unopened vials typically have a shelf life of 10 to 12 months
Meanwhile, Eli Lilly has told The Pharmaceutical Journal that its next wave of research would be focused on the potential of tailoring therapies to patient subgroups through biomarkers and precision medicine to understand who benefits most from each mechanism
At AMORE Health + Beauty, we provide advanced therapies to help patients achieve safe and sustainable weight management
doi: 10.1111/dom.12808